Can Gliclazide Cause Psychiatric Side Effects?
Gliclazide does not have well-documented psychiatric side effects based on FDA labeling and available evidence, though it may actually have a protective effect against depression according to recent research.
Direct Evidence from FDA Labeling
The FDA drug label for gliclazide (glipizide) lists the following adverse reactions 1:
- Common adverse effects include gastrointestinal disturbances, hypoglycemia, and allergic skin reactions
- Neurological effects documented are limited to: dizziness, drowsiness, and headache (occurring in approximately 1 in 50 patients)
- No psychiatric disorders are specifically listed as adverse reactions in the official labeling
The neurological symptoms (dizziness, drowsiness, headache) are typically transient and rarely require discontinuation of therapy 1.
Recent Research Findings
Protective Effect Against Depression
A 2025 cross-sectional study of 229 patients with type 2 diabetes found that sulfonylureas (including gliclazide) and glinides were associated with lower odds of depression (OR 0.374,95% CI: 0.182-0.768, P = 0.007) 2. This suggests gliclazide may actually have a beneficial rather than detrimental effect on mood.
No Association with Anxiety or Sleep Disorders
The same study found no significant associations between sulfonylureas and anxiety or sleep disturbances 2. By contrast, SGLT2 inhibitors were associated with poorer sleep quality, and insulin use was linked to increased anxiety in this population.
Important Clinical Caveats
Hypoglycemia-Related Psychiatric Symptoms
The primary psychiatric concern with gliclazide is indirect through hypoglycemia, not direct psychiatric toxicity:
- Severe hypoglycemia can cause confusion, altered mental status, and behavioral changes
- These are metabolic complications, not true psychiatric side effects
- Risk is higher in elderly patients and those with chronic kidney disease 3
Rare Neurological Toxicity in Overdose
One case report documented a 14-year-old who developed hemiplegia and dysphasia after a massive gliclazide overdose (20 mg/kg/day) in a suicide attempt 4. This represents severe neurotoxicity from overdose, not psychiatric side effects at therapeutic doses.
Clinical Recommendations
When prescribing gliclazide:
- Monitor for hypoglycemia symptoms (confusion, altered behavior) rather than primary psychiatric effects
- Consider gliclazide as potentially favorable for patients with comorbid depression compared to other antidiabetic agents
- Use caution with dosing in high-risk populations (elderly, renal impairment) to minimize hypoglycemia risk 3
- Educate patients that any mood or cognitive changes are more likely related to blood sugar fluctuations than direct drug effects
Gliclazide appears to be one of the safer antidiabetic medications from a psychiatric standpoint, with possible mood-protective benefits rather than psychiatric risks.